Reproductive Endocrinology Ovarian Hormones

Successful pregnancy using oral DHEA treatment for hypoandrogenemia in a 30-year-old female with 5 recurrent miscarriages, including fetal demise at 24 weeks: a case report

Boyle PC, Pandalache C, Turczynski C

Published March 2024 Frontiers in Medicine, 11, 1358563
DOI 10.3389/fmed.2024.1358563 PMID 38426161 PMC PMC10902037

RRM Academy Synopsis

Low androgens found after five pregnancy losses, then a healthy baby

An RRM clinic found low androgen hormones in a 30-year-old woman with five pregnancy losses, one at 24 weeks, that earlier testing had skipped. With treatment that included oral DHEA, she gave birth to a healthy boy at 36 weeks.

Study at a glance, case report of 30-year-old woman: Low androgens were found after five pregnancy losses
Study at a glance, case report of 30-year-old woman: Low androgens were found after five pregnancy losses. Source: Boyle PC et al., 2024, PMID 38426161.

Key Findings

  • Of her 6 pregnancies, 1 ended in a live birth and 5 in loss. One loss was fetal demise at 24 weeks, with no cause found.
  • The miscarriage clinic's workup after the 4th loss came back normal. Tissue from that 16-week loss showed triploidy.
  • At the RRM clinic in January 2022, she had hypoandrogenemia (low androgen levels) and poor follicle function.
  • Before conception she received follicle stimulation with clomiphene and oral DHEA. The DHEA went on through the pregnancy.
  • A cesarean at 36 weeks in November 2023 brought a healthy baby boy. Her earlier cesarean had left a thin uterine scar.

Interpretation

This case report describes one patient's workup and treatment. She also got follicle stimulation with clomiphene, hCG, naltrexone and progesterone, along with close cycle tracking. The authors say low androgens should be seen as a possible cause of repeat miscarriage or late pregnancy loss. They also say oral DHEA is safe and can help pregnancy outcomes. The findings support larger studies of this hormone-first approach.

RRM Context

RRM evaluation starts by asking why pregnancies were lost. The fifth loss here had no explanation, and the standard workup had left out androgens. The clinic used NeoFertility cycle tracking with blood tests on set days after ovulation. The authors credit the tracking app with helping across a language barrier. The report shows what a fresh look at hormone levels turned up in one woman.

Abstract

Hypoandrogenemia is not usually considered as a potential cause of recurrent miscarriage. We present the case of a 30-year-old female with 6 previous pregnancies resulting in one live birth and 5 pregnancy losses, including fetal demise at 24 weeks gestation. She had standard investigations after her 4th loss, at a specialized miscarriage clinic. Lupus anticoagulant, anticardiolipin antibodies, thyroid function, parental karyotypes were all normal. Fetal products confirmed triploidy for her 4th miscarriage at 16 weeks gestation. She was reassured and advised to conceive again but had fetal demise after 24 weeks gestation. This was her 5th pregnancy loss with no explanation. She attended our Restorative Reproductive Medicine (RRM) clinic in January 2022. In addition to poor follicle function, we found hypoandrogenemia for the first time. Treatment included follicle stimulation with clomiphene and DHEA 25 mg twice daily pre-conception with DHEA 20 mg once daily maintained throughout pregnancy. She delivered a healthy baby boy by cesarean section at 36 weeks gestation in November 2023. Hypoandrogenemia should be considered as a contributory factor for women with recurrent miscarriage or late pregnancy loss. Restoration of androgens to normal levels with oral DHEA is safe and can improve pregnancy outcome.

Read the guide

Topics

By this author

Related research

Reproductive Endocrinology › Ovarian Hormones › Androgens · Pregnancy › Pregnancy Complications › Hypertensive Disorders · Infertility › Recurrent Pregnancy Loss › Endocrine Causes
Phil C Boyle, Codruta Pandalache, Craig Turczynski
Philip Boyle, Phillip Boyle, P Boyle, C Pandalache, C Turczynski
PMID 38426161 38426161 DOI 10.3389/fmed.2024.1358563 10.3389/fmed.2024.1358563 Boyle et al. 2024, Boyle 2024